Trimetazidine in heart failure with preserved ejection fracton: a randomized, double-blind cross-over trial

Back

ESC Professional Premium Access

Trimetazidine in heart failure with preserved ejection fracton: a randomized, double-blind cross-over trial

Session: HFpEF and HFmrEF: what’s new in treatment?

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Mr A. van de Bovenkamp (Amsterdam, NL)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Mr Arno van de Bovenkamp

Amsterdam University Medical Centre, Amsterdam (Netherlands (The))

0 follower

4 more presentations in this session

Reduction in heart failure hospitalizations by sacubitril/valsartan; a post-hoc analysis of the PARALLAX trial

Speaker: Associate Professor R. Wachter (Leipzig, DE)

Effects of empagliflozin in patients with heart failure and preserved ejection fraction according to baseline diuretic use: results from the EMPEROR-Preserved trial

Speaker: Professor J. Butler (Dallas, US)

Association between use of renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors and beta-blockers and outcome in real-world heart failure and mildly reduced ejection fraction

Speaker: Doctor F. Lindberg (Stockholm, SE)

The therapeutic potential of relaxin for heart failure with preserved ejection fraction

Speaker: Doctor G. Salama (Pittsburgh, US)

Access the full session

HFpEF and HFmrEF: what’s new in treatment?

Speakers: Mr A. van de Bovenkamp, Associate Professor R. Wachter, Professor J. Butler, Doctor F. Lindberg, Doctor G. Salama

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources